Novo Nordisk
Pharmaceutical company manufacturing Wegovy (semaglutide) for weight management and type 2 diabetes
Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →
Key metrics · each point sourced
Stated objectives
Remove cost barriers to connect more people with innovative medicines through lower list prices
sourceComplete primary endpoint for CLEOPATTRA Phase 3 trial of coramitug in ATTR-CM
sourceExpand access to Wegovy and Ozempic for patients whose out-of-pocket costs are linked to list price, particularly those with high-deductible health plans or co-insurance benefit designs
sourceContinue to explore new therapies that deliver on weight loss needs while reducing the risk of obesity-related health issues like cardiovascular disease
sourceInvestigate the effect of CagriSema on cardiovascular outcomes in patients with established cardiovascular disease through REDEFINE 3 trial
sourceDevelop zaltenibart into a differentiated and potentially best-in-class treatment approach for rare blood and kidney disorders
sourceDeepen understanding of the many factors that shape the lived experience of obesity and strengthen support and care for the obesity community
sourceDrive more inclusive, compassionate approaches to obesity care that are tailored to individual circumstances
sourceInitiate late-stage clinical trials of experimental obesity drug amycretin in injectable and oral forms
sourceExpand manufacturing capacity to strengthen leadership in diabetes and obesity care market for GLP-1 products
source